Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Liquid biopsy in prostate cancer: A novel dual biomarker analysis approach integrating circulating tumor cells and circulating tumor DNA data.

Cellular and molecular biology (Noisy-le-Grand, France) - 8 Sept 2024

Li Qianyue, Tang Lei, Zhao Yawei, Li Zhikun, Ma Wang, Ma Liujiang

Abstract excerpt

This study aimed to explore the potential of liquid biopsy as a diagnostic tool by integrating two key biomarkers, Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA), and to enhance the detection fidelity of prostate cancer. A dual biomarker analysis approach was employed to synergize the sensitivities of CTCs and ctDNA. Various genetic mutations of ctDNA and tissues were scrutinized, investigating...

Topics

Join the communities discussing this publication.

Biomarkers, Tumor
Circulating Tumor DNA
Liquid Biopsy
Mutation
Neoplastic Cells, Circulating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Prostatic Neoplasms

Source

Identifiers

PMID: 39262247
DOI: 10.14715/cmb/2024.70.8.22

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liquid biopsy in prostate cancer: A novel dual biomarker analysis approach integrating circulating tumor cells and circulating tumor DNA data.PMID 39262247Read ↗

Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.Semantic proximity Read ↗

Multiparametric liquid biopsy analysis in metastatic prostate cancerSemantic proximity Read ↗

Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancerSemantic proximity Read ↗

Circulating Tumor DNA in Genitourinary Malignancies: Current Applications and Future PerspectivesSemantic proximity Read ↗

Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?Semantic proximity Read ↗

Blood-based liquid biopsy in advanced prostate cancer.Semantic proximity Read ↗

Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers.Semantic proximity Read ↗

TP53 Deficiency in the Natural History of Prostate CancerSemantic proximity Read ↗

Integrative genomic and epigenomic profiling in plasma and urinary cell-free DNA improves early risk stratification of newly diagnosed prostate cancerSemantic proximity Read ↗

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.Semantic proximity Read ↗

Liquid biopsy: a step forward towards precision medicine in urologic malignancies.Semantic proximity Read ↗

Technical and biological constraints on ctDNA-based genotyping.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.